To this point, we confirmed the improved IL-1β inhibitory potency of compound A over reference compound MCC950 in primary PBMC from a CAPS-patient diagnosed with Familial Cold Auto-inflammatory Syndrome (FCAS with L355P mutation in human NLRP3) and Neonatal Onset Multisystem Inflammatory Disease (NOMID with D305N mutation in human NLRP3) (Figs. 5L and EV4E). Here, IL1B is linked to Neonatal onset.